Wegovy (semaglutide) Weight Loss Injector 2.4 mg/0.75 mL

 

Wegovy is an injectable weight loss medication approved for adults with obesity or excess weight and weight-related conditions. It works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) to target areas of the brain that regulate appetite and food intake. The drug is designed for chronic weight management in patients with a body mass index (BMI) of 27 kg/m2 or greater who have at least one weight-related ailment, or in patients with a BMI of 30 kg/m2 or greater 3.

Wegovy (semaglutide) was approved by the U.S. Food and Drug Administration (FDA) for chronic weight management, marking the first time since 2014 that federal health authorities had green-lighted a new weight loss drug. The medication is used in addition to a reduced calorie diet and increased physical activity 3.

Wegovy should be administered as an under-the-skin injection and the dosing must be increased gradually over 16 to 20 weeks to 2.4 mg once weekly to minimize gastrointestinal side effects. However, it should not be used in combination with other semaglutide-containing products, GLP-1 receptor agonists, or other products intended for weight loss 3.

The common side effects of Wegovy include gastrointestinal issues like nausea, diarrhea, vomiting, and constipation, as well as headaches and fatigue. Some warnings and precautions are included in the prescribing information, such as the potential risk of thyroid C-cell tumors, history of certain medical conditions, and allergic reactions to the drug 3.

The drug's safety and efficacy were studied in four 68-week trials, which demonstrated significant weight loss in participants. However, there are specific criteria and precautions for its use, and it is important to discuss its usage with a healthcare professional, especially considering the potential side effects and cost implications 3